灵活评估平台研究中的代用性。

IF 1.8 3区 数学 Q3 MATHEMATICAL & COMPUTATIONAL BIOLOGY Biostatistics Pub Date : 2023-12-15 DOI:10.1093/biostatistics/kxac053
Michael C Sachs, Erin E Gabriel, Alessio Crippa, Michael J Daniels
{"title":"灵活评估平台研究中的代用性。","authors":"Michael C Sachs, Erin E Gabriel, Alessio Crippa, Michael J Daniels","doi":"10.1093/biostatistics/kxac053","DOIUrl":null,"url":null,"abstract":"<p><p>Trial-level surrogates are useful tools for improving the speed and cost effectiveness of trials but surrogates that have not been properly evaluated can cause misleading results. The evaluation procedure is often contextual and depends on the type of trial setting. There have been many proposed methods for trial-level surrogate evaluation, but none, to our knowledge, for the specific setting of platform studies. As platform studies are becoming more popular, methods for surrogate evaluation using them are needed. These studies also offer a rich data resource for surrogate evaluation that would not normally be possible. However, they also offer a set of statistical issues including heterogeneity of the study population, treatments, implementation, and even potentially the quality of the surrogate. We propose the use of a hierarchical Bayesian semiparametric model for the evaluation of potential surrogates using nonparametric priors for the distribution of true effects based on Dirichlet process mixtures. The motivation for this approach is to flexibly model relationships between the treatment effect on the surrogate and the treatment effect on the outcome and also to identify potential clusters with differential surrogate value in a data-driven manner so that treatment effects on the surrogate can be used to reliably predict treatment effects on the clinical outcome. In simulations, we find that our proposed method is superior to a simple, but fairly standard, hierarchical Bayesian method. We demonstrate how our method can be used in a simulated illustrative example (based on the ProBio trial), in which we are able to identify clusters where the surrogate is, and is not useful. We plan to apply our method to the ProBio trial, once it is completed.</p>","PeriodicalId":55357,"journal":{"name":"Biostatistics","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10939396/pdf/","citationCount":"0","resultStr":"{\"title\":\"Flexible evaluation of surrogacy in platform studies.\",\"authors\":\"Michael C Sachs, Erin E Gabriel, Alessio Crippa, Michael J Daniels\",\"doi\":\"10.1093/biostatistics/kxac053\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Trial-level surrogates are useful tools for improving the speed and cost effectiveness of trials but surrogates that have not been properly evaluated can cause misleading results. The evaluation procedure is often contextual and depends on the type of trial setting. There have been many proposed methods for trial-level surrogate evaluation, but none, to our knowledge, for the specific setting of platform studies. As platform studies are becoming more popular, methods for surrogate evaluation using them are needed. These studies also offer a rich data resource for surrogate evaluation that would not normally be possible. However, they also offer a set of statistical issues including heterogeneity of the study population, treatments, implementation, and even potentially the quality of the surrogate. We propose the use of a hierarchical Bayesian semiparametric model for the evaluation of potential surrogates using nonparametric priors for the distribution of true effects based on Dirichlet process mixtures. The motivation for this approach is to flexibly model relationships between the treatment effect on the surrogate and the treatment effect on the outcome and also to identify potential clusters with differential surrogate value in a data-driven manner so that treatment effects on the surrogate can be used to reliably predict treatment effects on the clinical outcome. In simulations, we find that our proposed method is superior to a simple, but fairly standard, hierarchical Bayesian method. We demonstrate how our method can be used in a simulated illustrative example (based on the ProBio trial), in which we are able to identify clusters where the surrogate is, and is not useful. We plan to apply our method to the ProBio trial, once it is completed.</p>\",\"PeriodicalId\":55357,\"journal\":{\"name\":\"Biostatistics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10939396/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biostatistics\",\"FirstCategoryId\":\"100\",\"ListUrlMain\":\"https://doi.org/10.1093/biostatistics/kxac053\",\"RegionNum\":3,\"RegionCategory\":\"数学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MATHEMATICAL & COMPUTATIONAL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biostatistics","FirstCategoryId":"100","ListUrlMain":"https://doi.org/10.1093/biostatistics/kxac053","RegionNum":3,"RegionCategory":"数学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

试验层面的代用指标是提高试验速度和成本效益的有用工具,但未经适当评估的代用指标可能会导致误导性结果。评估程序通常与具体情况有关,并取决于试验环境的类型。目前已有许多针对试验层面代用指标评估的方法,但据我们所知,还没有一种方法适用于平台研究的特定环境。随着平台研究越来越流行,我们需要使用平台研究进行代用评价的方法。这些研究还为代用评价提供了丰富的数据资源,这在通常情况下是不可能实现的。不过,它们也会带来一系列统计问题,包括研究人群、治疗方法、实施的异质性,甚至可能是代用指标的质量。我们建议使用分层贝叶斯半参数模型来评估潜在的代用品,该模型使用基于 Dirichlet 过程混合物的真实效应分布的非参数先验。采用这种方法的动机是灵活建模代用指标的治疗效果与结果的治疗效果之间的关系,并以数据驱动的方式识别具有不同代用指标价值的潜在群组,从而利用代用指标的治疗效果可靠地预测临床结果的治疗效果。在模拟实验中,我们发现我们提出的方法优于简单但相当标准的分层贝叶斯方法。我们在一个模拟示例(基于 ProBio 试验)中演示了如何使用我们的方法,在该示例中,我们能够识别代用指标有用或无用的群组。我们计划在 ProBio 试验完成后将我们的方法应用于该试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Flexible evaluation of surrogacy in platform studies.

Trial-level surrogates are useful tools for improving the speed and cost effectiveness of trials but surrogates that have not been properly evaluated can cause misleading results. The evaluation procedure is often contextual and depends on the type of trial setting. There have been many proposed methods for trial-level surrogate evaluation, but none, to our knowledge, for the specific setting of platform studies. As platform studies are becoming more popular, methods for surrogate evaluation using them are needed. These studies also offer a rich data resource for surrogate evaluation that would not normally be possible. However, they also offer a set of statistical issues including heterogeneity of the study population, treatments, implementation, and even potentially the quality of the surrogate. We propose the use of a hierarchical Bayesian semiparametric model for the evaluation of potential surrogates using nonparametric priors for the distribution of true effects based on Dirichlet process mixtures. The motivation for this approach is to flexibly model relationships between the treatment effect on the surrogate and the treatment effect on the outcome and also to identify potential clusters with differential surrogate value in a data-driven manner so that treatment effects on the surrogate can be used to reliably predict treatment effects on the clinical outcome. In simulations, we find that our proposed method is superior to a simple, but fairly standard, hierarchical Bayesian method. We demonstrate how our method can be used in a simulated illustrative example (based on the ProBio trial), in which we are able to identify clusters where the surrogate is, and is not useful. We plan to apply our method to the ProBio trial, once it is completed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biostatistics
Biostatistics 生物-数学与计算生物学
CiteScore
5.10
自引率
4.80%
发文量
45
审稿时长
6-12 weeks
期刊介绍: Among the important scientific developments of the 20th century is the explosive growth in statistical reasoning and methods for application to studies of human health. Examples include developments in likelihood methods for inference, epidemiologic statistics, clinical trials, survival analysis, and statistical genetics. Substantive problems in public health and biomedical research have fueled the development of statistical methods, which in turn have improved our ability to draw valid inferences from data. The objective of Biostatistics is to advance statistical science and its application to problems of human health and disease, with the ultimate goal of advancing the public''s health.
期刊最新文献
A Bayesian pharmacokinetics integrated phase I–II design to optimize dose-schedule regimes Dynamic and concordance-assisted learning for risk stratification with application to Alzheimer's disease. On the Addams family of discrete frailty distributions for modeling multivariate case I interval-censored data Pooling controls from nested case–control studies with the proportional risks model HMM for discovering decision-making dynamics using reinforcement learning experiments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1